Global Deferiprone Market By Formulation (Tablet, Oral Solution And Capsules), By Indication (Transfusional Iron Overload And Ntdt Caused Iron Overload), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Deferiprone Market By Formulation (Tablet, Oral Solution And Capsules), By Indication (Transfusional Iron Overload And Ntdt Caused Iron Overload), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)
Trusted Business Insights has published a comprehensive market research report on, Deferiprone Market by Formulation (Tablet, Oral Solution and Capsules), by Indication (Transfusional Iron Overload and NTDT Caused Iron Overload), and by Region -Global Forecast to 2030, which offers a holistic view of the Global Deferiprone Market through systematic segmentation that covers every aspect of the target market.


The Global Deferiprone market was valued at US$ 35.3 Mn in 2020 and is expected to reach US$ 38.4 Mn by 2030 at a CAGR of 0.9%.


Deferiprone is an iron chelator indicated for the treatment of patients with transfusional iron overload caused due to thalassemia syndromes, particularly when the current chelation therapy is inadequate. Chelation therapy is used to remove the build-up of toxic metals from the body, such as iron, lead, mercury, and arsenic, to prevent patients from getting severe thalassemia symptoms. Deferiprone (tradename Ferriprox), is an FDA approved the drug, majorly used to treat transfusion-dependent thalassemia and other related disorders. Patients with thalassemia can get a build-up of iron in their bodies, either from the disease or from recurrent blood transfusions. When the body is under primary iron overload condition or a secondary condition, caused due to lack of iron excretion mechanism, a massive accumulation of possibly toxic substances is experienced, which may lead to iron-induced early death. It is abundantly available, and evidence supports its use in the treatment of chronic iron overload. The drug is also associated with several adverse effects, including agranulocytosis, neutropenia, gastrointestinal symptoms such as nausea, vomiting, and abdominal pain, etc.

Rising prevalence of life-threatening disease -thalassemia among the population is expected to propel the growth of the global deferiprone market, thus growing incidence and prevalence of the disease is estimated to drive consumption of Deferiprone.

Furthermore, also, development and focus towards the provision and access to the populace in developing countries are likely to have a positive impact on the global deferiprone market.

Global Deferiprone Market Revenue (US$ Mn), 2021 to 2030

However, Deferiprone is considered genotoxic, carcinogenic, as well as teratogenic. The drug is only recommended when chelation therapy in patients is inadequate. The drug can cause side effects such as nausea, vomiting, stomach/ abdominal pain, joint pain, zinc deficiency and hypersensitivity in patients; this might hamper the growth of deferiprone market. Nonetheless, continuous R&D activities towards the use of deferiprone for treatment of other rare disorders is also expected to increase further adoption of the drug which is anticipated to boost market growth globally.
Global Deferiprone market is segmented on the basis of formulation, indication and region. On the basis of formulation, the market is segmented into a tablet, oral solution and capsules. Tablet segment accounts for the majority share in the global deferiprone market, while the oral solution is expected to register the highest growth rate over the forecast period. On the basis of indications, the market is segmented into Transfusional iron overload, and NTDT caused iron overload, and Transfusional iron overload accounts for a majority share in the global deferiprone market.

Global Deferiprone Market Attractiveness Analysis by Indication, 2012“2018

On the basis of region, the market is segmented into the United States, China, Europe, Japan, Southeast Asia, India and the rest of the world. The US accounts for the majority share in the global deferiprone market followed by Europe, owing to increasing government spending on healthcare in this region. Asia Pacific region, Japan, and the rest of the world are expected to register stable growth over the forecast period.

The research report on the global deferiprone market includes profiles of some of the major companies such as Cipla Limited, Apotex Inc., Swedish Orphan Biovitrum AB (publ), Genepharm S.A., Lipomed AG, Ambrosia Remedies (P) Ltd., and Focus Pharmaceuticals Limited.


Below are the active patents related to Deferiprone Market.

Patent Number: US8703156B2

Liquid formulation for deferiprone with palatable taste

Abstract

An oral pharmaceutical liquid formulation comprising deferiprone and a taste masking composition, said taste masking composition comprising an effective amount of a sweetener (such as sucralose) per liter of liquid composition, an effective amount of a thickening and suspension aid, (for example hydroxyethylcellulose), per liter of liquid composition, an effective amount of a humectant (such as glycerin) per liter of liquid composition, and an effective amount of at least one flavoring agent, wherein a final form of said taste-masked pharmaceutical has a substantially non-bitter and palatable taste.

Application File Date: 2008-04-25

Application Granted Date: 2014-04-22

Current Assignee: Chiesi Farmaceutici SpA

Patent Number: US20110039897A1

Liquid formulation for deferiprone with palatable taste

Abstract

An oral pharmaceutical liquid formulation comprising deferiprone and a taste masking composition, said taste masking composition comprising an effective amount of a sweetener (such as sucralose) per litre of liquid composition, an effective amount of a thickening and suspension aid, (for example hydroxyethylcellulose), per litre of liquid composition, an effective amount of a humectant (such as glycerin) per litre of liquid composition, and an effective amount of at least one flavoring agent, wherein a final form of said taste-masked pharmaceutical has a substantially non-bitter and palatable taste.

Application File Date: 2008-04-25

Application Granted Date: 2014-04-22

Current Assignee: Chiesi Farmaceutici SpA

Key Market Segments

By Formulation

Tablet
Oral solution
Capsules

By Indication

Transfusional iron overload
NTDT caused iron overload

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Key Market Players included in the report:
Ambrosia Remedies (P) Ltd.
Apotex Inc.
Cipla Limited.
Drug International Limited.
Focus Pharmaceuticals Limited.
Genepharm S.A.
Lipomed AG.
Swedish Orphan Biovitrum AB (publ).

Below are the key development related to Deferiprone Market in 2020 and 2021.

May 2021: Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease. Approval is based on demonstrated reduction in liver iron concentration.Expanded indications for patients with sickle cell disease or other anemias, as well as thalassemia. BOSTON, Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that the U.S. Food & Drug Administration (FDA) has approved FERRIPROX® (deferiprone) for the treatment of transfusional iron overload due to sickle cell disease (SCD) or other anemias in adult and pediatric patients 3 years of age and older. This FDA approval expands the use of FERRIPROX for patients with SCD or other anemias as well as patients with thalassemia regardless of prior iron chelation exposure. SCD affects about 100,000 people in the U.S. and leads to a lower life expectancy by more than 20 years compared to the general population. SCD patients are typically diagnosed prior to 2 years of age and the more severe patients start to experience pain crises early in childhood. Many require hospitalization and chronic blood transfusions to manage disease complications. Disease complications include early onset stroke, acute chest syndrome, and multiorgan failure. Renal complications affect nearly 30-50 percenti of patients with sickle cell anemia and account for 16-18 percent of mortality in adults with SCD.ii Source

September 2020: Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S. Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or “the Company”) announced the launch of a new specialty generic, deferiprone, an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®. This product expands Taro’s capabilities to include specialty products. Source

January 2020: Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone). Chiesi Group expands distribution network via acquisition for worldwide product rights. Chiesi Group will establish offices in Toronto, Canada. Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group) and Apotex, Inc., together with its US subsidiary, ApoPharma USA Inc., an innovative drug company, active in the hematology and neurodegeneration therapeutic areas, announced that Chiesi Group has finalized an agreement for the acquisition of the worldwide rights to Ferriprox® (deferiprone). Chiesi Group previously served as a distributor of Ferriprox® in Italy, Brazil, Turkey and certain other countries. Ferriprox® is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Thalassemia syndromes are a group of rare inherited hematological conditions including beta-thalassemia. With the agreement approved by all relevant regulatory authorities, the Ferriprox® franchise will become part of the Chiesi Group’s growing portfolio of rare disease products. The team of approximately 50 ApoPharma employees will transition to Chiesi Group, providing a foundation for Chiesi to establish offices in Toronto, Canada. Source